The FDA decision on ARS Pharmaceuticals Inc’s (SPRY) request seeking to expand the use of neffy for children who weigh 15 to 30 kg is due on March 6, 2025.Neffy is an intranasal epinephrine product. It secured FDA approval in August 2024 for the emergency treatment of allergic reactions (Type 1), including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater.Preliminary neffy net product revenue for the fourth quarter of 2024 was approximately $6.5 million.Updated on March 6: The FDA approved the expanded use of neffy on Mar.5.SPRY closed Wednesday’s (Mar.5, 2025) trading at $10.87, up 3.43%.